A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants

References

• Callaway E. Heavily mutated coronavirus variant puts scientists on alert. Nature. 2021;600(7887):21–21. doi:10.1038/D41586-021-03552-W
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi:10.1038/s41586-021-04389-z
   PubMed Web of Science ®Google Scholar
• Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468–470. doi:10.1056/NEJMc2207519
   PubMed Web of Science ®Google Scholar
• Miller J, Hachmann NP, Collier AY, et al. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388:662–664. doi:10.1056/NEJMc2214314
   PubMed Web of Science ®Google Scholar
• Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. Lancet. 2019;393:1392–1394. doi:10.1016/S0140-6736(18)32326-2
   PubMed Web of Science ®Google Scholar
• Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–19. doi:10.1086/505147
   PubMed Web of Science ®Google Scholar
• Chitalia VC, Munawar AH. A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. J Transl Med. 2020;18:390. doi:10.1186/s12967-020-02476-9
   PubMed Web of Science ®Google Scholar
• Murgolo N, Therien AG, Howell B, et al. SARS-CoV-2 tropism, entry, replication, and propagation: considerations for drug discovery and development. PLoS Pathog. 2021;17:e1009225. doi:10.1371/journal.ppat.1009225
   PubMed Web of Science ®Google Scholar
• Shagufta AI. The race to treat COVID-19: potential therapeutic agents for the prevention and treatment of SARS-CoV-2. Eur J Med Chem. 2021;213:113157. doi:10.1016/j.ejmech.2021.113157
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. N Engl J Med. 2020;383:1813–1826. doi:10.1056/NEJMoa2007764
   PubMed Web of Science ®Google Scholar
• Arch B, Kovacs D, Scott J, et al. Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO clinical characterisation protocol UK: a prospective, national cohort study. medRxiv. 2021; 2021.06.18.21259072.
   Google Scholar
• Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi:10.1126/science.abl4784
   PubMed Web of Science ®Google Scholar
• Ledford H, Maxmen A. African clinical trial denied access to key COVID drug Paxlovid. Nature. 2022;604:412–413. doi:10.1038/d41586-022-01069-4
   PubMed Web of Science ®Google Scholar
• Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369–1377. doi:10.1097/00002030-200107270-00006
   PubMed Web of Science ®Google Scholar
• Hussain M, Galvin HD, Haw TY, et al. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017;10:121–134. doi:10.2147/IDR.S105473
   PubMed Web of Science ®Google Scholar
• Stanciu C, Muzica CM, Girleanu I, et al. An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother. 2021;22:1729–1741. doi:10.1080/14656566.2021.1921737
   PubMed Web of Science ®Google Scholar
• Jochmans D, Liu C, Donckers K, et al. The substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. mBio. 2023. doi:10.1128/MBIO.02815-22/SUPPL_FILE/MBIO.02815-22-S0004.DOCX
   PubMed Web of Science ®Google Scholar
• Ranganath N, O’Horo JC, Challener DW, et al. Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease-2019 in high-risk persons. Clin Infect Dis. 2023;76:e537–e539. doi:10.1093/cid/ciac481
   PubMed Web of Science ®Google Scholar
• Ip JD, Wing-Ho Chu A, Chan W-M, et al. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance. EBioMedicine. 2023;91:104559. doi:10.1016/j.ebiom.2023.104559
   PubMed Web of Science ®Google Scholar
• Mody V, Ho J, Wills S, et al. Identification of 3-chymotrypsin like protease (3CLpro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biol. 2021;4(1):1–10. doi:10.1038/s42003-020-01566-0
   PubMed Web of Science ®Google Scholar
• Shi J, Wei Z, Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors*. J Biol Chem. 2004;279:24765–24773. doi:10.1074/jbc.M311744200
   PubMed Web of Science ®Google Scholar
• Silvestrini L, Belhaj N, Comez L, et al. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors. Sci Rep. 2021;11:1–16. doi:10.1038/s41598-020-79139-8
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003;300:1763–1767. doi:10.1126/science.1085658
   PubMed Web of Science ®Google Scholar
• Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA. 2003;100:13190–13195. doi:10.1073/pnas.1835675100
   PubMed Web of Science ®Google Scholar
• Xue X, Yu H, Yang H, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82:2515–2527. doi:10.1128/JVI.02114-07
   PubMed Web of Science ®Google Scholar
• Kneller DW, Phillips G, O’Neill HM, et al. Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun. 2020;11(1):1–6. doi:10.1038/s41467-019-13872-1
   PubMed Web of Science ®Google Scholar
• Lee J, Worrall LJ, Vuckovic M, et al. Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nat Commun. 2020;11:1–9. doi:10.1038/s41467-019-13993-7
   PubMed Web of Science ®Google Scholar
• Callaway E. Beyond Omicron: what’s next for COVID’s viral evolution. Nature. 2021;600:204–207. doi:10.1038/d41586-021-03619-8
   PubMed Web of Science ®Google Scholar
• Indari O, Jakhmola S, Manivannan E, et al. An update on antiviral therapy against SARS-CoV-2: how far have We come? Front Pharmacol. 2021;0:133.
   Google Scholar
• Douangamath A, Fearon D, Gehrtz P, et al. Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease. Nat Commun. 2020;11:1–11. doi:10.1038/s41467-019-13993-7
   PubMed Web of Science ®Google Scholar
• Shapira T, Monreal IA, Dion SP, et al. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605:340–348. doi:10.1038/s41586-022-04661-w
   PubMed Web of Science ®Google Scholar
• Pérez-Vargas J, Shapira T, Olmstead AD, et al. Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics. Antiviral Res. 2023;209:105484. doi:10.1016/j.antiviral.2022.105484
   PubMed Web of Science ®Google Scholar
• Tang J, Wennerberg K, Aittokallio T. What is synergy? The Saariselkä agreement revisited. Front Pharmacol. 2015;6:1–6. doi:10.3389/fphar.2015.00181
   PubMed Web of Science ®Google Scholar
• Yadav B, Wennerberg K, Aittokallio T, et al. Searching for drug synergy in complex dose–response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504–513. doi:10.1016/j.csbj.2015.09.001
   PubMed Web of Science ®Google Scholar
• Zheng S, Wang W, Aldahdooh J, et al. Synergyfinder plus: toward better interpretation and annotation of drug combination screening datasets. Genomics Proteomics Bioinformatics. 2022. doi:10.1016/j.gpb.2022.01.004
   Web of Science ®Google Scholar
• Sacco MD, Ma C, Lagarias P, et al. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Adv. 2020: 6. doi:10.1126/SCIADV.ABE0751
   Web of Science ®Google Scholar
• Hamill P, Hudson D, Kao RY, et al. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata. Biol Chem. 2006;387:1063–1074. doi:10.1515/BC.2006.131
   PubMed Web of Science ®Google Scholar
• Meyer B, Chiaravalli J, Gellenoncourt S, et al. Characterising proteolysis during SARS-CoV-2 infection identifies viral cleavage sites and cellular targets with therapeutic potential. Nat Commun. 2021;12:1–16. doi:10.1038/s41467-020-20314-w
   PubMed Web of Science ®Google Scholar
• Jean F, Basak A, Dimaio J, et al. An internally quenched fluorogenic substrate of prohormone convertase 1 and furin leads to a potent prohormone convertase inhibitor. Biochem J. 1995;307:689–695. doi:10.1042/bj3070689
   PubMed Web of Science ®Google Scholar
• Yaron A, Carmel A, Katchalski-Katzir E. Intramolecularly quenched fluorogenic substrates for hydrolytic enzymes. Anal Biochem. 1979;95:228–235. doi:10.1016/0003-2697(79)90210-0
   PubMed Web of Science ®Google Scholar
• Froggatt HM, Heaton BE, Heaton NS. Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay. J Virol. 2020;94; doi:10.1128/JVI.01265-20
   PubMed Web of Science ®Google Scholar
• Citarella A, Scala A, Piperno A, et al. SARS-CoV-2 mpro: a potential target for peptidomimetics and small-molecule inhibitors. Biomolecules. 2021;11:607. doi:10.3390/biom11040607
   PubMed Web of Science ®Google Scholar
• Cons BD, Twigg DG, Kumar R, et al. Electrostatic complementarity in structure-based drug design. J Med Chem. 2022;65:7476–7488. doi:10.1021/acs.jmedchem.2c00164
   PubMed Web of Science ®Google Scholar
• Hou N, Shuai L, Zhang L, et al. Development of highly potent noncovalent inhibitors of SARS-CoV-2 3CLpro. ACS Cent Sci. 2022. doi:10.1021/ACSCENTSCI.2C01359/ASSET/IMAGES/LARGE/OC2C01359_0006.JPEG
   Web of Science ®Google Scholar
• Plante JA, Mitchell BM, Plante KS, et al. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021;29:508–515. doi:10.1016/j.chom.2021.02.020
   PubMed Web of Science ®Google Scholar
• Poutanen SM. Human Coronaviruses. Principles and Practice of Pediatric Infectious Diseases. 2012:1117–1120.e4. doi:10.1016/B978-1-4377-2702-9.00224-5.
   Google Scholar
• Shitrit A, Zaidman D, Kalid O, et al. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Sci Rep. 2020;10:20808. doi:10.1038/s41598-020-77794-5
   PubMed Web of Science ®Google Scholar
• Chang FY, Brady SF. Discovery of indolotryptoline antiproliferative agents by homology-guided metagenomic screening. Proc Natl Acad Sci USA. 2013;110:2478–2483. doi:10.1073/pnas.1222125110
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: The XBB.1.5 (‘Kraken’) subvariant of Omicron SARS-CoV-2 and its rapid global spread. Med Sci Monit. 2023;29:e939580-1.
   Web of Science ®Google Scholar
• Lewnard JA, Hong V, Kim JS, et al. Increased vaccine sensitivity of an emerging SARS-CoV-2 variant. medRxiv. 2023. 2023.03.11.23287148.
   PubMedGoogle Scholar
• Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA. 1988;85:7972–7976. doi:10.1073/pnas.85.21.7972
   PubMed Web of Science ®Google Scholar
• Greasley SE, Noell S, Plotnikova O, et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J Biol Chem. 2022;298:101972. doi:10.1016/j.jbc.2022.101972
   PubMed Web of Science ®Google Scholar
• Drayman N, DeMarco JK, Jones KA, et al. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Science. (1979) 2021;373:931–936. doi:10.1126/science.abg5827
   Google Scholar
• Kim Y, Shivanna V, Narayanan S, et al. Broad-Spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses. J Virol. 2015;89:4942–4950. doi:10.1128/JVI.03688-14
   PubMed Web of Science ®Google Scholar
• Tzou PL, Tao K, Nouhin J, et al. Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds. Viruses. 2020;12:1006. doi:10.3390/v12091006
   PubMed Web of Science ®Google Scholar
• Dampalla CS, Zheng J, Dinali Perera K, et al. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc Natl Acad Sci USA. 2021. doi:10.1073/pnas.2101555118
   PubMed Web of Science ®Google Scholar
• Su H, Yao S, Zhao W, et al. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease. Nat Commun. 2021;12:1–12. doi:10.1038/s41467-020-20314-w
   PubMed Web of Science ®Google Scholar
• Singh J, Anantharaj A, Panwar A, et al. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. PLoS Pathog. 2023;19:e1011196. doi:10.1371/journal.ppat.1011196
   PubMed Web of Science ®Google Scholar
• Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:322–324. doi:10.1038/s41422-022-00618-w
   PubMed Web of Science ®Google Scholar
• Schultz DC, Johnson RM, Ayyanathan K, et al. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature. 2022;604:134–140. doi:10.1038/s41586-022-04482-x
   PubMed Web of Science ®Google Scholar